Literature DB >> 26206083

MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1.

Lixue Gu1, Weiming Sun2.   

Abstract

MicroRNAs (miRNAs) are important regulators of multiple cellular processes, and aberrant miRNA expression has been observed in thyroid cancer. However, the role of miRNAs in thyroid cancer metastasis remains largely unknown. In the current study, we found that miR-539 plays a suppressor role in thyroid cancer cell migration and invasion. Luciferase reporter assays confirmed that miR-539 binding to the 3'-UTR region of CARMA1 inhibited the expression of CARMA1 in thyroid cancer cells. Further studies demonstrated that CARMA1 can significantly promote the migration and invasion of thyroid cancer cells. Interestingly, overexpression or knockdown of CARMA1 effectively blocked the effect of miR-539 on the migration and invasion of thyroid cancer cells. Furthermore, we showed that miR-539 expression was frequently downregulated and CARMA1 expression was significantly upregulated in thyroid cancer cell lines and thyroid cancer tissues compared with controls. Taken together, our data indicate that miR-539 is a novel regulator of migration and invasion in human thyroid cancer cells by targeting CARMA1.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  CARMA1; Invasion; MicroRNA-539; Migration; Thyroid cancer

Mesh:

Substances:

Year:  2015        PMID: 26206083     DOI: 10.1016/j.bbrc.2015.07.090

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.

Authors:  Rui Li; Jia Liu; Qun Li; Guang Chen; Xiaofang Yu
Journal:  Tumour Biol       Date:  2015-10-19

2.  microRNA-141 inhibits thyroid cancer cell growth and metastasis by targeting insulin receptor substrate 2.

Authors:  Su Dong; Xianying Meng; Shuai Xue; Zewen Yan; Peiyou Ren; Jia Liu
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

3.  Long noncoding RNA LINC00339 promotes the oncogenicity of gastric cancer by regulating SRY-box 9 expression via sponging of microRNA-539.

Authors:  Hui Zhao; Hongyu Xiao; Yi Lu; Shen Liu; Cheng Wang
Journal:  Cell Cycle       Date:  2020-04-19       Impact factor: 4.534

4.  MicroRNA-539 inhibits colorectal cancer progression by directly targeting SOX4.

Authors:  Jian Zhao; Jian Xu; Rui Zhang
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

5.  Long Non-coding RNA LINC00339 Stimulates Glioma Vasculogenic Mimicry Formation by Regulating the miR-539-5p/TWIST1/MMPs Axis.

Authors:  Junqing Guo; Heng Cai; Xiaobai Liu; Jian Zheng; Yunhui Liu; Wei Gong; Jiajia Chen; Zhuo Xi; Yixue Xue
Journal:  Mol Ther Nucleic Acids       Date:  2017-11-26       Impact factor: 8.886

Review 6.  miRNA dysregulation and the risk of metastasis and invasion in papillary thyroid cancer: a systematic review and meta-analysis.

Authors:  Tiantian Wang; Hao Xu; Ming Qi; Sheng Yan; Xingsong Tian
Journal:  Oncotarget       Date:  2017-03-29

7.  Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma.

Authors:  Alireza Mirghasemi; Afshin Taheriazam; Seyyed Hasan Karbasy; Ali Torkaman; Mohammadreza Shakeri; Emad Yahaghi; Aram Mokarizadeh
Journal:  Cancer Cell Int       Date:  2015-09-17       Impact factor: 5.722

8.  miR-539 inhibits prostate cancer progression by directly targeting SPAG5.

Authors:  Hongtuan Zhang; Shadan Li; Xiong Yang; Baomin Qiao; Zhihong Zhang; Yong Xu
Journal:  J Exp Clin Cancer Res       Date:  2016-04-01

9.  miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer.

Authors:  Jilong Guo; Guohua Gong; Bin Zhang
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

10.  Circular RNA Circ_0067934 Attenuates Ferroptosis of Thyroid Cancer Cells by miR-545-3p/SLC7A11 Signaling.

Authors:  Hui-Hui Wang; Jia-Ni Ma; Xiao-Rong Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.